Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wyeth Plans to Apply for Prevenar in Japan in 2007
November 27, 2006
- Dainippon Sumitomo Preparing Plan for Overseas Business Expansion
November 20, 2006
- Taisho: Sales of OTC, Ethical Drugs Down in 1st Half
November 20, 2006
- Shionogi: Sluggish Sales of Antibiotics Hurt 1st-Half Results
November 20, 2006
- Tanabe Seiyaku to Announce Generic Business Plan by Next March
November 20, 2006
- Ono: Generic Competition Impacts Sales of Major Products
November 20, 2006
- Midterm Plan to Focus on Improving Profit Structure: Santen
November 20, 2006
- Meiji Seika Licenses Penem, Antithrombotic Agents to US Companies
November 20, 2006
- BUSINESS NEWS IN BRIEF
November 20, 2006
- Henry McKinnell Decorated with Grand Cordon: Pfizer Japan
November 20, 2006
- Information Disclosure Key to Better Industry Image in Japan
November 20, 2006
- 7th Kitasato University-Harvard School of Public Health Symposium -1-
November 20, 2006
- 7th Kitasato University-Harvard School of Public Health Symposium -2-
November 20, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 20, 2006
- R&D NEWS IN BRIEF
November 20, 2006
- Takeda Seeking Acquisition Opportunities in Specific Fields
November 20, 2006
- NEW PRODUCTS
November 20, 2006
- Astellas to Embark on Asian Studies
November 20, 2006
- Medtronic Opens Training Center
November 20, 2006
- Daiichi Sankyo: Olmetec/Benicar Drove Increase in Sales
November 20, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…